BofA update shows where active managers are putting money
Halozyme Therapeutics Inc. has reached an all-time high, with its stock price hitting 73.5 USD. This milestone marks a significant achievement for the company, which now commands a market capitalization of $8.56 billion and boasts an impressive 52.54% year-to-date return, reflecting investor confidence and positive market sentiment. Over the past year, Halozyme Therapeutics has experienced a 13.55% increase in its stock value, supported by robust revenue growth of 35% and an "Excellent" Financial Health Score according to InvestingPro. The company’s innovative approaches and strategic partnerships continue to drive its upward momentum in the market, attracting attention from both investors and industry analysts. For deeper insights into Halozyme’s potential, InvestingPro offers 19 additional investment tips and a comprehensive Pro Research Report, part of their coverage of 1,400+ top US stocks.
In other recent news, Halozyme Therapeutics reported its second-quarter 2025 earnings, revealing a mixed performance with an earnings per share (EPS) of $1.54, surpassing the projected $1.24. However, the company’s revenue fell short of expectations, coming in at $206 million compared to the anticipated $286.01 million. Following these financial results, Citizens JMP raised its price target for Halozyme to $91, maintaining a Market Outperform rating, and noted that the company had exceeded both its and consensus estimates. Additionally, Halozyme raised its top-line and bottom-line guidance for 2025. In a separate development, Morgan Stanley upgraded Halozyme to Overweight, increasing the price target to $75. The upgrade was influenced by the passage of the One Big Beautiful Bill, which includes the ORPHAN Cures Act, expected to benefit Halozyme. Furthermore, Goldman Sachs adjusted its price target for Halozyme to $56, maintaining a Neutral rating. This adjustment followed an analysis of potential impacts from upcoming CMS guidance on the Inflation Reduction Act for Part B drugs. These developments highlight significant recent changes for Halozyme.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.